---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-26-000002"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:32.543933+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FTC injunction blocks Edwards' JenaValve acquisition; Edwards raises FY2026 EPS guidance to $2.90-$3.05

## Summary
- US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.
- Edwards revises FY2026 adjusted EPS guidance upward to $2.90-$3.05 from $2.80-$2.95.
- Edwards disagrees with ruling, remains committed to AR therapy; advancing SOJOURN valve and JOURNEY trial.
- Additional updates expected at Q4 earnings call in February.

## SEC filing metadata
- accession: 0001099800-26-000002
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000002/0001099800-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000002/ew-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-26-000002
- JSON: https://secwatch.observer/filing/0001099800-26-000002.json
- Plain text: https://secwatch.observer/filing/0001099800-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.